HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS British Journal of Psychiatry Advances in Psychiatric Treatment All RCPsych Journals		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Smith, S. Articles by Atmakur, P. Search for Related Content PubMed Articles by Smith, S. Articles by Atmakur, P.

L-tryptophan for treatment-resistant depression

Specialist Registrar, Henry Lautch Centre, Bushey Fields Hospital, Bushey Fields Road, Dudley

Praveen Atmakur

Senior House Officer

L-tryptophan, the amino acid precursor of serotonin, is not widely used as an adjunctive treatment despite its recommendation in treatment-resistant depression (Taylor, 2001).

Perhaps inexperience, limited supporting data (Shaw et al, 2002), or the inconvenience of full blood count monitoring and patient registration deter prescribers. Numerous authors have reported on mood changes associated with L-tryptophan depletion (including Bell et al, 2001), but few recent studies consider efficacy. We wish to report our experience of L-tryptophan (Optimax) use.

A complete list of patients prescribed L-tryptophan between 1999-2002 under the care of one consultant psychiatrist was obtained from the central Optimax registration service. Fifty-three individuals were identified, of whom 52 case records were available. Response to augmentation as measured on Optimax monitoring forms was recorded (no response, satisfactory, good), along with details of continuation or cessation and reasons for discontinuation.

Thirty-two patients were female, twenty male. The age range was 22–66 (average age 45.4 years).

Twenty-nine patients (56%) reported an improvement in mood following commencement of L-tryptophan (23% satisfactory, 33% good). Twenty-three (44%) reported no response.

Eight patients discontinued L-tryptophan following recovery. Twentyone discontinued for other reasons: lack of response (ten), reluctance to take L-tryptophan (two), following overdose (one), feeling worse (one), side-effects (six), unspecified (one). The side-effects reported were stiffness (one), irritability (one), dizziness (two), unspecified (two). No patients ceased treatment as a result of developing eosinophilia or symptoms of eosinophilia myalgia. Eighty-six per cent of the patient sample tolerated L-tryptophan.

Although unsophisticated, these results support the use of L-tryptophan as an augmentation strategy in treatment-resistant depression, bringing about symptom improvement in 56% of the sample. This compares favourably to the published 50-60% response rate with lithium augmentation.

References

BELL, C., ABRAMS, J. & NUTT, D. (2001) Tryptophan depletion and its implications for psychiatry. British Journal of Psychiatry, 178, 399 –405.[Abstract/Free Full Text]

SHAW, K., TURNER, J. & DEL MAR, C. (2002) Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Systematic Review: CD003198. London: The Cochrane Library.

TAYLOR, D. (2001) The South London & Maudsley NHS Trust 2001 Prescribing Guidelines, 6th edn. London: Taylor & Francis.

This Article Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Smith, S. Articles by Atmakur, P. Search for Related Content PubMed Articles by Smith, S. Articles by Atmakur, P.